Chinese biotechnology giant WuXi Apptec , will raise HK$7.70 billion ($980.93 million) through share placement, in a bid to ...

WuXi XDC cited strong demand for antibody-drug conjugates, which are widely used in targeted cancer treatments, and for ...

A solid run for Hong Kong stocks showed signs of cracking, as the city’s benchmark headed for a two-week low after the US ...

SHANGHAI, June 18 (Reuters) - Drug research and development firms in China including WuXi AppTec (603259.SS), opens new tab and WuXi Biologics (2269.HK), opens new tab are changing project plans ...

[SINGAPORE] Shanghai-based airline Juneyao Air is restarting its service between Singapore and Wuxi on Aug 29, having last ...

WuXi AppTec, China's leading CXO, is trading at a price-to-earnings (P/E) ratio of 21 times, much lower than the 30 times for Asymchem Laboratories (6821.HK).

CHENGDU, China, June 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has kicked ...

Zhang lived abroad for more than 20 years and speaks Korean fluently. When she came back to Wuxi, she wanted to help Korean ...

Wuxi Apptec said on Thursday it will be raising HK$7.70 billion ($980.98 million) through a share placement to aid its global ...